Abstract 5057
Background
Breast cancer is second leading cause of cancer-related-deaths in women, supporting the need for the detection of novel prognostic biomarkers for risk stratification. There is growing body of evidence showing the association of common genetic variants on chromosome 9p21 with an increased risk of developing different tumors and metabolic disorders. Here we investigated the association of a genetic variant in CDKN2A/B, rs1333049, for the first time in 303 subjects with and without breast cancer.
Methods
Method: Genotyping was carried out using TaqMan real time PCR method in case and control groups. The associations of this genetic variant were evaluated with breast cancer risk and pathological information of patients.
Results
We observed that the minor allele homozygote situation of this genetic variant in total population was 10%, while this condition in heterozygote was 38%. the logistic regression under recessive genetic model revealed that breast cancer patients with GG genotype had higher risk of breast cancer, compared to CC/CG genotypes (e.g., OR = 2.8, 95% CI:1.4-5.4, p = 0.001), after adjusted for age, and BMI.
Conclusions
We demonstrated that patients carrying the GG genotype for CDKN2A/B rs1333049 polymorphism had an increased risk of breast cancer susceptibility, indicating further studies in a larger and prospective setting to show the value of emerging marker as a risk stratification biomarker in breast cancer.
Clinical trial identification
Legal entity responsible for the study
Mashhad University of Medical Sciences, Mashhad, Iran.
Funding
Mashhad University of Medical Sciences, Mashhad, Iran.
Editorial Acknowledgement
Mashhad University of Medical Sciences, Mashhad, Iran.
Disclosure
All authors have declared no conflicts of interest.